Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Elevated levels of miR-181c and miR-633 in the CSF of patients with MS: A validation study.

Kramer S, Haghikia A, Bang C, Scherf K, Pfanne A, Duscha A, Kaisler J, Gisevius B, Gold R, Thum T, Haghikia A.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 1;6(6):e623. doi: 10.1212/NXI.0000000000000623. Print 2019 Nov.

2.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
3.

Implications of Diet and The Gut Microbiome in Neuroinflammatory and Neurodegenerative Diseases.

Hirschberg S, Gisevius B, Duscha A, Haghikia A.

Int J Mol Sci. 2019 Jun 25;20(12). pii: E3109. doi: 10.3390/ijms20123109. Review.

4.

Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis.

Zorlu N, Hoffjan S, Haghikia A, Deyneko IV, Epplen JT.

J Neuroimmunol. 2019 Sep 15;334:576979. doi: 10.1016/j.jneuroim.2019.576979. Epub 2019 Jun 4.

PMID:
31181469
5.

Prediction of heart failure and death in an adult population of Fontan patients.

Sieweke JT, Haghikia A, Riehle C, Klages C, Akin M, König T, Zwadlo C, Treptau J, Schäfer A, Bauersachs J, Westhoff-Bleck M.

Cardiol Young. 2019 May;29(5):602-609. doi: 10.1017/S1047951119000258. Epub 2019 Apr 30.

PMID:
31036097
6.

Functional Neurosonology Reveals Impaired Cerebrovascular Reactivity in Multiple Sclerosis.

Krogias C, Christou I, Tsivgoulis G, Koutroulou I, Schroeder C, Lantinioti C, Richter D, Karapanayiotides T, Haghikia A, Gold R, Voumvourakis K.

J Neuroimaging. 2019 Sep;29(5):589-591. doi: 10.1111/jon.12617. Epub 2019 Apr 16.

PMID:
30990241
7.

Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients.

Gast M, Rauch B, Haghikia A, Nakagawa S, Haas J, Stroux A, Schmidt D, Schumann P, Weiss S, Jensen L, Kratzer A, Kraenkel N, Müller C, Börnigen D, Hirose T, Blankenberg S, Escher F, Kühl A, Kuss A, Meder B, Landmesser U, Zeller T, Poller W.

Cardiovasc Res. 2019 Mar 29. pii: cvz085. doi: 10.1093/cvr/cvz085. [Epub ahead of print]

PMID:
30924864
8.

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis.

Vohl K, Duscha A, Gisevius B, Kaisler J, Gold R, Haghikia A.

Front Neurol. 2019 Feb 22;10:132. doi: 10.3389/fneur.2019.00132. eCollection 2019.

9.

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G.

Ann Neurol. 2019 Apr;85(4):606-610. doi: 10.1002/ana.25437. Epub 2019 Mar 5.

PMID:
30761586
10.

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.

Zella MAS, Metzdorf J, Ostendorf F, Maass F, Muhlack S, Gold R, Haghikia A, Tönges L.

Cells. 2019 Jan 31;8(2). pii: E105. doi: 10.3390/cells8020105. Review.

11.

Treatment of an acute motor and sensory axonal neuropathy with propionate in a 33-year-old male.

Yoon MS, Pitarokoili K, Sturm D, Haghikia A, Gold R, Fisse AL.

Ther Adv Neurol Disord. 2018 Nov 3;11:1756286418809580. doi: 10.1177/1756286418809580. eCollection 2018.

12.

Successful therapy with rituximab in three patients with probable neurosarcoidosis.

Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J.

Ther Adv Neurol Disord. 2018 Oct 26;11:1756286418805732. doi: 10.1177/1756286418805732. eCollection 2018.

13.

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.

Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A.

J Neurol. 2019 Jan;266(1):57-67. doi: 10.1007/s00415-018-9092-4. Epub 2018 Oct 30.

14.

Editorial commentary: Peripartum cardiomyopathy: Long-term implications of treatment and management.

Haghikia A, Hilfiker-Kleiner D.

Trends Cardiovasc Med. 2019 Apr;29(3):174-175. doi: 10.1016/j.tcm.2018.09.001. Epub 2018 Sep 6. No abstract available.

PMID:
30219276
15.

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction.

Haghikia A, Schwab J, Vogel-Claussen J, Berliner D, Pfeffer T, König T, Zwadlo C, Moulig VA, Franke A, Schwarzkopf M, Ehlermann P, Pfister R, Michels G, Westenfeld R, Stangl V, Kühl U, Podewski E, Kindermann I, Böhm M, Sliwa K, Hilfiker-Kleiner D, Bauersachs J.

Clin Res Cardiol. 2019 Mar;108(3):290-297. doi: 10.1007/s00392-018-1355-7. Epub 2018 Aug 18.

16.

Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice.

Gast M, Rauch BH, Nakagawa S, Haghikia A, Jasina A, Haas J, Nath N, Jensen L, Stroux A, Böhm A, Friebel J, Rauch U, Skurk C, Blankenberg S, Zeller T, Prasanth KV, Meder B, Kuss A, Landmesser U, Poller W.

Cardiovasc Res. 2019 Feb 1;115(2):302-314. doi: 10.1093/cvr/cvy202.

PMID:
30101304
17.

Effects of Apolipoprotein A-I/High-Density Lipoprotein Cholesterol on Atherosclerotic Vascular Disease: Critical Impact of Atherosclerosis Disease Stage and Disease Milieu?

Haghikia A, Landmesser U.

JACC Basic Transl Sci. 2018 May 30;3(2):210-212. doi: 10.1016/j.jacbts.2018.03.003. eCollection 2018 Apr. No abstract available.

18.

Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes.

Haghikia A, Li XS, Liman TG, Bledau N, Schmidt D, Zimmermann F, Kränkel N, Widera C, Sonnenschein K, Haghikia A, Weissenborn K, Fraccarollo D, Heimesaat MM, Bauersachs J, Wang Z, Zhu W, Bavendiek U, Hazen SL, Endres M, Landmesser U.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2225-2235. doi: 10.1161/ATVBAHA.118.311023.

19.

Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT.

Derlin T, Sedding DG, Dutzmann J, Haghikia A, König T, Napp LC, Schütze C, Owsianski-Hille N, Wester HJ, Kropf S, Thackeray JT, Bankstahl JP, Geworski L, Ross TL, Bauersachs J, Bengel FM.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1934-1944. doi: 10.1007/s00259-018-4076-2. Epub 2018 Jul 3.

20.

Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis.

Schroeder C, Back C, Koc Ü, Strassburger-Krogias K, Reinacher-Schick A, Gold R, Haghikia A.

Clin Neurol Neurosurg. 2018 Sep;172:24-26. doi: 10.1016/j.clineuro.2018.06.005. Epub 2018 Jun 23.

PMID:
29960102
21.

Cardiovascular Involvement in Chronic Hepatitis C Virus Infections - Insight from Novel Antiviral Therapies.

Poller W, Haghikia A, Kasner M, Kaya Z, Bavendiek U, Wedemeier H, Epple HJ, Skurk C, Landmesser U.

J Clin Transl Hepatol. 2018 Jun 28;6(2):161-167. doi: 10.14218/JCTH.2017.00057. Epub 2018 Jan 26. Review.

22.

Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.

Motte J, Kneiphof J, Straßburger-Krogias K, Klasing A, Adams O, Haghikia A, Gold R.

J Neurol. 2018 Aug;265(8):1880-1882. doi: 10.1007/s00415-018-8931-7. Epub 2018 Jun 15.

PMID:
29948248
23.

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis.

Hammer A, Waschbisch A, Kuhbandner K, Bayas A, Lee DH, Duscha A, Haghikia A, Gold R, Linker RA.

Ann Clin Transl Neurol. 2018 Apr 16;5(6):668-676. doi: 10.1002/acn3.553. eCollection 2018 Jun.

24.

Impacts of microbiome metabolites on immune regulation and autoimmunity.

Haase S, Haghikia A, Wilck N, Müller DN, Linker RA.

Immunology. 2018 Jun;154(2):230-238. doi: 10.1111/imm.12933. Epub 2018 Apr 30. Review.

25.

High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response.

Haghikia A, Landmesser U.

Cardiol Clin. 2018 May;36(2):317-327. doi: 10.1016/j.ccl.2017.12.013. Review.

PMID:
29609761
26.

[Nutrition, microbiome and multiple sclerosis : Current knowledge from basic research and clinical practice].

Haghikia A, Linker RA.

Nervenarzt. 2018 Apr;89(4):463-471. doi: 10.1007/s00115-018-0497-1. German.

PMID:
29516151
27.

Western lifestyle and immunopathology of multiple sclerosis.

Matveeva O, Bogie JFJ, Hendriks JJA, Linker RA, Haghikia A, Kleinewietfeld M.

Ann N Y Acad Sci. 2018 Apr;1417(1):71-86. doi: 10.1111/nyas.13583. Epub 2018 Jan 27. Review.

28.

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 Signaling for Effects of Fumaric Acid Esters on Dendritic Cells.

Hammer A, Waschbisch A, Knippertz I, Zinser E, Berg J, Jörg S, Kuhbandner K, David C, Pi J, Bayas A, Lee DH, Haghikia A, Gold R, Steinkasserer A, Linker RA.

Front Immunol. 2017 Dec 22;8:1922. doi: 10.3389/fimmu.2017.01922. eCollection 2017.

29.

Dietary fatty acids and susceptibility to multiple sclerosis.

Haase S, Haghikia A, Gold R, Linker RA.

Mult Scler. 2018 Jan;24(1):12-16. doi: 10.1177/1352458517737372. Review.

PMID:
29307296
30.

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.

Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, Schwarzkopf M, Ehlermann P, Pfister R, Michels G, Westenfeld R, Stangl V, Kindermann I, Kühl U, Angermann CE, Schlitt A, Fischer D, Podewski E, Böhm M, Sliwa K, Bauersachs J.

Eur Heart J. 2017 Sep 14;38(35):2671-2679. doi: 10.1093/eurheartj/ehx355.

31.

Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation.

Hammer A, Schliep A, Jörg S, Haghikia A, Gold R, Kleinewietfeld M, Müller DN, Linker RA.

J Neuroinflammation. 2017 Sep 12;14(1):184. doi: 10.1186/s12974-017-0954-y.

32.

Lipoproteins and Cardiovascular Redox Signaling: Role in Atherosclerosis and Coronary Disease.

Haghikia A, Landmesser U.

Antioxid Redox Signal. 2018 Jul 20;29(3):337-352. doi: 10.1089/ars.2017.7052. Epub 2017 Dec 1. Review.

PMID:
28817963
33.

Testosterone Differentially Affects T Cells and Neurons in Murine and Human Models of Neuroinflammation and Neurodegeneration.

Massa MG, David C, Jörg S, Berg J, Gisevius B, Hirschberg S, Linker RA, Gold R, Haghikia A.

Am J Pathol. 2017 Jul;187(7):1613-1622. doi: 10.1016/j.ajpath.2017.03.006.

PMID:
28634006
34.

Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Thackeray JT, Pietzsch S, Stapel B, Ricke-Hoch M, Lee CW, Bankstahl JP, Scherr M, Heineke J, Scharf G, Haghikia A, Bengel FM, Hilfiker-Kleiner D.

JCI Insight. 2017 May 18;2(10). pii: 93098. doi: 10.1172/jci.insight.93098. eCollection 2017 May 18.

35.

Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.

Nonhoff J, Ricke-Hoch M, Mueller M, Stapel B, Pfeffer T, Kasten M, Scherr M, von Kaisenberg C, Bauersachs J, Haghikia A, Hilfiker-Kleiner D.

Cardiovasc Res. 2017 May 1;113(6):598-608. doi: 10.1093/cvr/cvw245.

36.

Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).

Schneider R, Bellenberg B, Hoepner R, Kolb EM, Ellrichmann G, Haghikia A, Gold R, Lukas C.

PLoS One. 2017 Apr 26;12(4):e0176415. doi: 10.1371/journal.pone.0176415. eCollection 2017.

37.

Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy.

Hilfiker-Kleiner D, Haghikia A, Masuko D, Nonhoff J, Held D, Libhaber E, Petrie MC, Walker NL, Podewski E, Berliner D, Bauersachs J, Sliwa K.

Eur J Heart Fail. 2017 Dec;19(12):1723-1728. doi: 10.1002/ejhf.808. Epub 2017 Mar 27.

38.

The role of L-arginine/L-homoarginine/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients.

Haghikia A, Yanchev GR, Kayacelebi AA, Hanff E, Bledau N, Widera C, Sonnenschein K, Haghikia A, Weissenborn K, Bauersachs J, Bavendiek U, Tsikas D.

Amino Acids. 2017 Jun;49(6):1111-1121. doi: 10.1007/s00726-017-2409-2. Epub 2017 Mar 11.

PMID:
28285332
39.

Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.

Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, Silvola JM, Roivainen A, Saraste A, Nickel AG, Saar JA, Sieve I, Pietzsch S, Müller M, Bogeski I, Kappl R, Jauhiainen M, Thackeray JT, Scherr M, Bengel FM, Hagl C, Tudorache I, Bauersachs J, Maack C, Hilfiker-Kleiner D.

Eur Heart J. 2017 Feb 1;38(5):349-361. doi: 10.1093/eurheartj/ehw086.

40.

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.

Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R.

Lancet Neurol. 2017 Feb;16(2):104-106. doi: 10.1016/S1474-4422(16)30382-9. No abstract available.

PMID:
28102146
41.

Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study.

Haghikia A, Röntgen P, Vogel-Claussen J, Schwab J, Westenfeld R, Ehlermann P, Berliner D, Podewski E, Hilfiker-Kleiner D, Bauersachs J.

ESC Heart Fail. 2015 Dec;2(4):139-149. Epub 2015 Sep 30.

42.

Nerve ultrasound protocol in differentiating chronic immune-mediated neuropathies.

Kerasnoudis A, Pitarokoili K, Haghikia A, Gold R, Yoon MS.

Muscle Nerve. 2016 Nov;54(5):864-871. doi: 10.1002/mus.25138. Epub 2016 Sep 21.

PMID:
27061901
43.

Active immunotherapy may delay disability in progressive MS.

Haghikia A, Gold R.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):193. doi: 10.1136/jnnp-2016-314377. Epub 2016 Sep 28. No abstract available.

PMID:
27683917
44.

The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.

Berg J, Mahmoudjanlou Y, Duscha A, Massa MG, Thöne J, Esser C, Gold R, Haghikia A.

J Neuroimmunol. 2016 Sep 15;298:9-15. doi: 10.1016/j.jneuroim.2016.06.003. Epub 2016 Jun 9.

PMID:
27609269
45.

Environmental factors in autoimmune diseases and their role in multiple sclerosis.

Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M.

Cell Mol Life Sci. 2016 Dec;73(24):4611-4622. Epub 2016 Aug 4. Review.

46.

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.

Akin M, Skripuletz T, Napp LC, Berliner D, Akin I, Haghikia A, Akin E, Bauersachs J.

Cardiovasc Hematol Agents Med Chem. 2017;14(2):94-100. doi: 10.2174/1871525714666160727113740. Review.

PMID:
27470008
47.

Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Linker RA, Haghikia A.

Ther Adv Chronic Dis. 2016 Jul;7(4):198-207. doi: 10.1177/2040622316653307. Epub 2016 Jun 10. Review.

48.

Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.

Décard BF, Thöne J, Haghikia A, Börnke C, Anders A, Lukas C, Gold R.

Mult Scler. 2017 Jan;23(1):123-125. doi: 10.1177/1352458516650522. Epub 2016 Jul 20.

PMID:
27430683
49.

Immunoadsorption in patients with neuromyelitis optica spectrum disorder.

Faissner S, Nikolayczik J, Chan A, Gold R, Yoon MS, Haghikia A.

Ther Adv Neurol Disord. 2016 Jul;9(4):281-6. doi: 10.1177/1756285616646332. Epub 2016 May 15.

50.

Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.

Massa MG, Gisevius B, Hirschberg S, Hinz L, Schmidt M, Gold R, Prochnow N, Haghikia A.

PLoS One. 2016 May 9;11(5):e0155274. doi: 10.1371/journal.pone.0155274. eCollection 2016.

Supplemental Content

Loading ...
Support Center